Skip to main content Back to Top
Advertisement

11/29/2021

Octreotide Injection

Products Affected - Description

    • Octreotide Acetate injection, Fresenius Kabi, 100 mcg/mL, 1 mL vial, 10 count, NDC 63323-0376-01
    • Octreotide Acetate injection, Fresenius Kabi, 1000 mcg/mL, 5 mL vial, 1 count, NDC 63323-0379-05
    • Octreotide Acetate injection, Sagent, 1000 mcg/mL, 5 mL vial, 1 count, NDC 25021-0467-05
    • Octreotide Acetate injection, Sagent, 1000 mcg/mL, 5 mL vial, 1 count, NDC 25021-0455-05 - discontinued
    • Octreotide Acetate injection, Sagent, 200 mcg/mL, 5 mL vial, 1 count, NDC 25021-0454-05 - discontinued
    • Octreotide Acetate injection, Sagent, 200 mcg/mL, 5 mL vial, 1 count, NDC 25021-0466-05
    • Octreotide Acetate injection, Teva, 200 mcg/mL, 5 mL vial, 1 count, NDC 00703-3333-01
    • Octreotide Acetate injection, Teva, 50 mcg/mL, 1 mL vial, 25 count, NDC 00703-3301-04
    • Octreotide Acetate injection, Teva, 500 mcg/mL, 1 mL vial, 25 count, NDC 00703-3321-04

Reason for the Shortage

    • Fresenius Kabi had octreotide on shortage due to manufacturing delays.
    • Hikma did not provide a reason for the shortage.
    • Mylan Institutional did not provide a reason for the shortage.
    • Sagent discontinued octreotide 200 mcg/mL 5 mL vials and 1,000 mcg/mL 5 mL vials, but are relaunching new NDCs in 2022.
    • Sun Pharma has Bynfezia Pen available.
    • Teva had octreotide on shortage due to increased demand.
    • Novartis has Sandostatin available. The 200 mcg/mL 5 mL vials were discontinued in early-2018.

Available Products

    • Bynfezia Pen injection, Sun Pharma, 2,500 mcg/mL, 2.8 mL single-use pen injector, 1 count, NDC 62756-0452-36
    • Bynfezia Pen injection, Sun Pharma, 2,500 mcg/mL, 2.8 mL single-use pen injector, 2 count, NDC 62756-0452-37
    • Sandostatin injection, Novartis, 100 mcg/mL, 1 mL ampule, 10 count, NDC 00078-0181-01
    • Sandostatin injection, Novartis, 50 mcg/mL, 1 mL ampule, 10 count, NDC 00078-0180-01
    • Sandostatin injection, Novartis, 500 mcg/mL, 1 mL ampule, 10 count, NDC 00078-0182-01
    • Octreotide Acetate injection, Fresenius Kabi, 200 mcg/mL, 5 mL vial, 1 count, NDC 63323-0378-05
    • Octreotide Acetate injection, Fresenius Kabi, 500 mcg/mL, 1 mL vial, 10 count, NDC 63323-0377-01
    • Octreotide Acetate injection, Hikma, 1,000 mcg/mL, 5 mL multiple dose vial, 1 count, NDC 00641-6178-10
    • Octreotide Acetate injection, Hikma, 100 mcg/mL, 1 mL vial, 10 count, NDC 00641-6175-10
    • Octreotide Acetate injection, Hikma, 200 mcg/mL, 5 mL multiple dose vial, 1 count, NDC 00641-6177-10
    • Octreotide Acetate injection, Hikma, 50 mcg/mL, 1 mL vial, 10 count, NDC 00641-6174-10
    • Octreotide Acetate injection, Hikma, 500 mcg/mL, 1 mL vial, 10 count, NDC 00641-6176-10
    • Octreotide Acetate injection, Mylan Institutional, 100 mcg/mL, 1 mL syringe, 10 count, NDC 67457-0245-01
    • Octreotide Acetate injection, Mylan Institutional, 50 mcg/mL, 1 mL syringe, 10 count, NDC 67457-0239-01
    • Octreotide Acetate injection, Mylan Institutional, 500 mcg/mL, 1 mL syringe, 10 count, NDC 67457-0246-01
    • Octreotide Acetate injection, Sagent, 100 mcg/mL, 1 mL vial, 10 count, NDC 25021-0452-01
    • Octreotide Acetate injection, Sagent, 50 mcg/mL, 1 mL vial, 10 count, NDC 25021-0451-01
    • Octreotide Acetate injection, Sagent, 500 mcg/mL, 1 mL vial, 10 count, NDC 25021-0453-01
    • Octreotide Acetate injection, Teva, 100 mcg/mL, 1 mL vial, 25 count, NDC 00703-3311-04
    • Octreotide Acetate injection, Teva, 1000 mcg/mL, 5 mL vial, 1 count, NDC 00703-3343-01

Estimated Resupply Dates

    • Fresenius Kabi has octreotide 1,000 mcg/mL 5 mL vials on back order and the company estimates a release date of early-December 2021. The 100 mcg/mL 1 mL vials are on back order and the company estimates a release date of late-December 2021.
    • Teva has octreotide 50 mcg/mL 1 mL vials, 500 mcg/mL 1 mL vials, and 200 mcg/mL 5 mL vials on back order and the company cannot estimate a release date.
    • Sagent has 200 mcg/mL 5 mL vials and 1,000 mcg/mL 5 mL vials on back order and the company estimates a relaunch date of March 2022.

Updated

Updated November 29, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. Created March 16, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2021, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.